Integration of SPECT/CT Lymphoscintigraphy Into Breast Cancer Radiation for LymphaticSparing
- To assess the feasibility of integrating Philips Precedence SPECT/CT® images with GE
PET/CT Fusion software to reduce radiation dosimetry delivered to lymph nodes draining
the arm in patients after surgery for stage I or II breast cancer.
- To examine the differences in radiation dosimetry in these patients using 3-D conformal
radiotherapy with vs without the Philips Precedence SPECT/CT®.
- To compare reduction in lymph node radiation dosimetry in these patients using single
photon emission computed tomography (SPECT) and computed tomography (CT) with 3-D
conformal radiotherapy vs intensity-modulated radiotherapy.
OUTLINE: Patients receive filtered technetium Tc 99m sulfur colloid (TcSC) intradermally and
undergo single photon emission computed tomography (SPECT) and computed tomography (CT)
imaging at the time of TcSC and 2 hours after injection. Patients then undergo
intensity-modulated radiotherapy of the whole breast, including the low axilla and lymph
nodes identified by the Phillips Precedence SPECT/CT® at a dose determined by computer
analysis of the imaging information.
Patients complete a lymphedema screening questionnaire at baseline and at 12 and 24 months
Masking: Open Label, Primary Purpose: Diagnostic
Philips Precedence SPECT/CT® and GE PET/CT Fusion software integration
Andrea L. Cheville, MD, PhD
United States: Federal Government
|Mayo Clinic||Rochester, Minnesota 55905|